BiotechTube

CT-P53 + US-Ocrevus + EU-Ocrevus

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing-remitting Multiple Sclerosis

Conditions

Relapsing-remitting Multiple Sclerosis

Trial Timeline

Jan 11, 2024 → Jan 1, 2029

NCT ID
NCT05906992

About CT-P53 + US-Ocrevus + EU-Ocrevus

CT-P53 + US-Ocrevus + EU-Ocrevus is a phase 3 stage product being developed by Celltrion for Relapsing-remitting Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05906992. Target conditions include Relapsing-remitting Multiple Sclerosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05906992Phase 3Recruiting

Competing Products

20 competing products in Relapsing-remitting Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
LY2127399 + PlaceboEli LillyPhase 2
52
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
52
DaclizumabAbbViePhase 3
77
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
52
BIIB019 (Daclizumab)AbbViePhase 3
77
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
77
Rebif (Interferon beta-1a)MerckPre-clinical
23
Interferon beta-1aMerckPre-clinical
23
Rebif® + Avonex®MerckPhase 3
77
Rebif® + Rebif®MerckApproved
85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
52
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
52
Interferon beta-1a (Rebif)MerckApproved
85
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
77
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
77
Interferon beta 1aMerckPre-clinical
23
Cladribine 10 mg oral tabletMerckApproved
85
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + TecfideraMerckPhase 2
52
Minocycline + PlaceboMerckPhase 2
52

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85